Akebia Therapeutics Inc. (AKBA)
Akebia Therapeutics, Inc. (AKBA) Q2 2026 Earnings Call Transcript
Akebia Therapeutics, Inc. (AKBA) Q2 2026 Earnings Call Transcript
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to break-even earnings per share a year ago.
Akebia Therapeutics Q2 Earnings Call Highlights
Akebia Therapeutics NASDAQ: AKBA reported second-quarter revenue growth for its Vafseo anemia treatment while highlighting an interim clinical result from the VOICE study and progress across its kidney disease pipeline.
Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near
Akebia Therapeutics NASDAQ: AKBA outlined its commercial priorities for Vafseo, the expected evolution of reimbursement after the TDAPA period and several renal-disease pipeline programs during a fireside chat at the Jefferies 2026 Global Healthcare Conference.
Akebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call Transcript
Akebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call Transcript
New Strong Sell Stocks for April 28th
EADSY, AKBA and AMTB have been added to the Zacks Rank #5 (Strong Sell) List on April 28, 2026.
Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D Day Transcript
Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D Day Transcript
Is the Options Market Predicting a Spike in Akebia Therapeutics Stock?
Investors need to pay close attention to AKBA stock based on the movements in the options market lately.
Akebia Therapeutics, Inc. (AKBA) Presents at Leerink Global Healthcare Conference 2026 Transcript
Akebia Therapeutics, Inc. (AKBA) Presents at Leerink Global Healthcare Conference 2026 Transcript
Akebia Therapeutics, Inc. (AKBA) Q4 2025 Earnings Call Transcript
Akebia Therapeutics, Inc. (AKBA) Q4 2025 Earnings Call Transcript
Akebia Therapeutics, Inc. (AKBA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Akebia Therapeutics, Inc. (AKBA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts
Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts
